Category Archives: Antiandrogens

What happened, proxalutamide? New antiandrogen for COVID-19 is entangled in clinical data irregularities and human rights violations

Posted on December 1, 2021 by Zinnia Jones

Disclaimer: I am not a medical professional and this is not medical advice. From the outset of the COVID-19 pandemic, there has been interest in a possible relationship between sex hormones and likelihood of infection or severity of disease. Cis … Continue reading →

Posted in Antiandrogens, COVID-19, Endocrinology, Ethics, News | Tagged , , , | Leave a comment

Denmark population-wide study confirms association between cyproterone acetate and meningioma risk – and recent users of CPA are disproportionately trans women

Posted on August 1, 2021 by Zinnia Jones

Previously: Additional data confirms 10mg of cyproterone acetate (CPA) is effective for testosterone suppression in trans women (June 2021) Disclaimer: I am not a medical professional and this is not medical advice. Since 2018, I’ve been covering emerging findings on … Continue reading →

Posted in Antiandrogens, Endocrinology, Oncology, Progestogens, Transfeminine, Transgender medicine | Tagged , , , | Leave a comment

Additional data confirms 10mg of cyproterone acetate (CPA) is effective for testosterone suppression in trans women

Posted on June 30, 2021 by Zinnia Jones

Previously: Lower doses of cyproterone acetate may be similarly effective for blocking testosterone, with a lower risk of adverse effects (August 2020) Study of entire French population offers further data on cyproterone acetate and meningioma risk (February 2021) Disclaimer: I … Continue reading →

Posted in Antiandrogens, Endocrinology, Oncology, Progestogens, Transgender medicine | Tagged , , | Leave a comment

Study of entire French population offers further data on cyproterone acetate and meningioma risk

Posted on February 28, 2021 by Zinnia Jones

Previously: Cyproterone acetate and meningioma risk in trans women (March 2018) Update on case reports: Cyproterone acetate and meningioma in trans women (November 2018) Lower doses of cyproterone acetate may be similarly effective for blocking testosterone, with a lower risk … Continue reading →

Posted in Antiandrogens, Endocrinology, Oncology, Progestogens | Tagged , , | Leave a comment

Proxalutamide, a new antiandrogen, improves COVID-19 outcomes in trials of men and women

Posted on February 28, 2021 by Zinnia Jones

Previously: COVID-19 updates: From spironolactone to estrogen to GnRH antagonists (May 2020) Disclaimer: I am not a medical professional and this is not medical advice. The COVID-19 pandemic continues to be a rapidly evolving situation, and this information may be … Continue reading →

Posted in Antiandrogens, COVID-19, Endocrinology | Tagged , , | Leave a comment